ASA404

DRUG8 trials

Sponsors

Novartis Pharmaceuticals, University of California, San Francisco, Hoosier Cancer Research Network

Conditions

Advanced Solid TumorsHistologically-proven and Radiologically-confirmed Solid TumorsMetastatic Cancer With Impaired Renal FunctionMetastatic Cancer With Normal Renal FunctionNon-Small Cell Lung CancerNon-small Cell Lung CancerTumorsUrothelial Carcinoma

Phase 1

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00674102

Novartis PharmaceuticalsNon-small Cell Lung Cancer

Start: 2008-04-30Updated: 2020-12-09

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

WithdrawnNCT01031212

University of California, San FranciscoTumors

Start: 2010-01-31End: 2013-06-30Updated: 2013-05-13

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

TerminatedNCT01240642

Novartis PharmaceuticalsMetastatic Cancer With Impaired Renal Function, Metastatic Cancer With Normal Renal Function

Start: 2010-01-31Updated: 2020-12-09

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

TerminatedNCT01278849

Novartis PharmaceuticalsHistologically-proven and Radiologically-confirmed Solid Tumors

Start: 2010-01-31Updated: 2020-12-09

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

TerminatedNCT01299701

Novartis PharmaceuticalsAdvanced Solid Tumors

Start: 2008-12-31End: 2009-07-31Updated: 2017-02-14

Phase 2

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

WithdrawnNCT01071928

Hoosier Cancer Research NetworkUrothelial Carcinoma

Start: 2010-06-30End: 2010-06-30Updated: 2015-08-19

Phase 3

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

TerminatedNCT00662597

Novartis PharmaceuticalsNon-Small Cell Lung Cancer

Start: 2008-04-30End: 2010-05-31Updated: 2020-12-24

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

TerminatedNCT00738387

Novartis PharmaceuticalsNon-Small Cell Lung Cancer

Start: 2008-12-31Updated: 2020-12-24